ClinicalTrials.gg
CompletedNCT01499004Updated Jan 12, 2012

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

A Phase 1 interventional study of tofacitinib (CP-690,550) modified-release formulation A and tofacitinib (CP-690,550) modified-release formulation B1 in Healthy, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-12.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.

02

Conditions studied

  • Healthy

Keywords

  • tofacitinib
  • CP-690
  • 550
  • relative bioavailability
  • modified release
  • Phase 1
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects and/or healthy females subjects who are of non-.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease;
  • Clinically significant infections within the past 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment A

    tofacitinib (CP-690,550) modified-release formulation A-Fed

    Drug: tofacitinib (CP-690,550) modified-release formulation A

  • Experimental
    Treatment B

    tofacitinib (CP-690,550) modified-release formulation B1-Fed

    Drug: tofacitinib (CP-690,550) modified-release formulation B1

  • Experimental
    Treatment C

    tofacitinib (CP-690,550) modified-release formulation A-Fasted

    Drug: tofacitinib (CP-690,550) modified-release formulation A

  • Experimental
    Treatment D

    tofacitinib (CP-690,550) modified-release formulation B1-Fasted

    Drug: tofacitinib (CP-690,550) modified-release formulation B1

  • Experimental
    Treatment E

    tofacitinib (CP-690,550) modified-release formulation B2-Fasted

    Drug: tofacitinib (CP-690,550) modified-release formulation B2

  • Experimental
    Treatment F

    tofacitinib (CP-690,550) immediate-release formulation-Fasted

    Drug: tofacitinib (CP-690,550) immediate-release formulation

Interventions

06

What researchers measure

Primary outcomes

  1. AUCinf: Area under the plasma concentration-time profile from time 0 exprapolated to infinite time

    Time frame: 72 hours post dose

  2. AUClast: Area under the plasma concentration-time profile from time 0 to the last with quantifiable concentration

    Time frame: 72 hours post dose

  3. Cmax: Maximum plasma concentration of tofacitinib (CP-690,550)

    Time frame: 72 hours post dose

  4. Tmax: Amount of time tofacitinib (CP-690,550) is at maximum plasma concentration

    Time frame: 72 hours post dose

  5. t1/2: The time required for one half of the total amount of tofacitinib (CP-690,550) to be removed from the plasma

    Time frame: 72 hours post dose

Secondary outcomes

  1. Frel: Relative bioavailability (Frel) of tofacitinib (CP-690,550) in the modified-release formulations compared to the immediate release formulation

    Time frame: 24 hours post dose

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2011
First posted
Dec 26, 2011
Start
Nov 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Jan 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01499004
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Nov 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Jan 12, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion